Dexamethasone ophthalmic - EyeGate Pharma

Drug Profile

Dexamethasone ophthalmic - EyeGate Pharma

Alternative Names: BLO 022; EGP-437

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator EyeGate Pharma
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratoplasty rejection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular inflammation; Uveitis
  • Phase I/II Retinal oedema
  • Phase I Retinal disorders
  • Suspended Dry eyes; Scleritis
  • No development reported Keratoplasty rejection

Most Recent Events

  • 21 Feb 2017 Global manufacturing and commercial rights to ophthalmic dexamethasone and EyeGate® II delivery system combination product licensed to Valeant Pharmaceuticals, for the treatment of post-operative ocular pain and inflammation
  • 23 Jan 2017 EyeGate Pharma has patent protection for dexamethasone ophthalmic in Canada, USA, Mexico, Australia and Israel
  • 23 Jan 2017 EyeGate Pharma has patents pending for dexamethasone ophthalmic in Brazil and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top